JS1-1-01
Phase 3Small molecule
Tasly Pharmaceutical Group Co., LtdJS1-1-01 is one of 2 small molecule programs targeting Severe Depression. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Severe Depression
#DrugCompanyPhaseTrials
1Ketalar
AAultman Health Foundation
Phase 3
JS1-1-01
Tasly Pharmaceutical Group Co., LtdPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Severe Depression2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JS1-1-01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details